Testing changed immune cells for glioblastoma that has come back
Original title: A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early first test of this treatment in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests changed immune cells in people whose glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary has come back.
Who this trial is for. This trial is for people whose glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary has come back. It tests immune cells, called NK cells, that were changed in a lab.
Where it stands. This trial has not reported results. The team is trying to find the best way to give these cells to patients. That answer is not in yet.
What this means, and what it doesn't
What it could mean: Nothing here shows that this treatment works. If it sounds like it might fit you, you can ask your care team about it. They can help you think it through.
What it doesn't mean: This does not mean there is a new treatment for glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary. A trial is a test, not proven care. Joining one does not promise that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 25, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.